MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse

MLA

Chen, Weihao, et al. “MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 4816–18. EBSCOhost, https://doi.org/10.1182/blood-2022-166696.

APA

Chen, W., Huang, L., Shi, Z., Shi, J., Luo, Y., Yu, J., Lai, X., Liu, L., Fu, H., Zheng, Z., Huang, H., & Zhao, Y. (2022). MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse. Blood, 140(Supplement 1), 4816–4818. https://doi.org/10.1182/blood-2022-166696

Chicago

Chen, Weihao, Luo Huang, Zhuoyue Shi, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, et al. 2022. “MRD Monitoring of Non-DTA Genes By Digital Droplet PCR in the Early Period after Allogeneic Hematopoietic Stem Cell Transplantation Can Effectively Predict Patients at High Risk of Relapse.” Blood 140 (Supplement 1): 4816–18. doi:10.1182/blood-2022-166696.